SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) saw a significant growth in short interest in October. As of October 15th, there was short interest totaling 1,344 shares, a growth of 78.0% from the September 30th total of 755 shares. Based on an average daily volume of 53,601 shares, the days-to-cover ratio is currently 0.0 days.
SAB Biotherapeutics Price Performance
Shares of NASDAQ SABSW remained flat at $0.00 during mid-day trading on Friday. SAB Biotherapeutics has a fifty-two week low of $0.00 and a fifty-two week high of $0.20. The company has a 50-day moving average of $0.01 and a 200 day moving average of $0.02.
SAB Biotherapeutics Company Profile
SAB Biotherapeutics, Inc is a biotechnology company focused on developing antibody-based medicines for infectious diseases, autoimmune conditions and other immune-mediated disorders. The company’s lead programs have included SAB-142, an investigational therapy for immune-mediated disease, and SAB-176, an antibody product candidate designed to address influenza A infections. SAB also developed SAB-185 for the treatment of COVID-19.
The company uses its DiversitAb platform, which involves genetically engineered cattle capable of producing fully human polyclonal antibodies.
Featured Stories
- Five stocks we like better than SAB Biotherapeutics
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
